Biology

IIBR leads na​tional efforts to counter any and all biological threats from intentional attacks as well as naturally-emerging diseases. Using a multi-disciplinary project strategy, combined with cutting edge technologies, we develop methods for the identification of various bio-threats; forensic investigation of bio-terror agents and pathogenesis mech​anisms; design of new strategies for vaccine development, as well as evaluation of novel modalities of therapeutics. IIBR biotechnology cGMP multi-product facility, is designed for the development and production of bio-pharmaceuticals and unique vaccines for national preparedness. ​

EXPLORE
COVID - 19
 

Environmental science

IIBR research and development concerning environmental sciences ranges from numerical mod​eling to laboratory and field​​​​ experiments in the areas of meteorology and atmospheric contaminants. IIBR has developed capabilities that enable detection and identification of hazardous materials, weather and dispersion prediction, physical protection and evaluation of potential risks.

EXPLORE
 

Chemistry

Toxicological eval​uation at IIBR is followed by the generation of novel treatment protocols and drugs, rapid and effective solutions for damage prevention and control. These are g​ained by a combination of cutting-edge synthetic capabilities and an advanced analytical toolbox. All are based on comprehensive pharmacological and pathophysiological understanding and advanced experimental means.​

EXPLORE
 
Collaborate

PHD

Women In Science

0

Fields of scientific knowledge

0

Last decade publications

PM Netanyahu, Gantz and Edelstein visited The Israel Institute for Biological research

​During the visit, IIBR leading scientists gave an update about the scientific developments and the following steps on the way to develop a vaccine and a treatment for the Corona virus.​​

 

 

An analogue of Cerdelga®, an FDA-approved drug, is effective against a broad range of RNA-viruses including SARS-CoV-2

New study examined the antiviral effect of two specific inhibitors of GlucosylCeramide synthase (GCS): (1) an analogue of the FDA-approved drug Cerdelga®, (2) an analogue of venglustat which is currently under phase III clinical trials. Our findings show that both inhibitors inhibit the replication of four different enveloped RNA viruses of different genus, organ-target and transmission route including SARS-Cov-2. The fact that these inhibitors have an antiviral effect on viruses of four different families, suggesting a key role of the glycosphingolipid synthesis pathway in viral infection. Targeting host proteins or pathways utilized by multiple viruses is less prone to the development of resistance to the drug through mutations. ​

 

 

The President to the state of Israel's visit to The Israel Institute for biological research (IIBR)

​During the president’s visit, IIBR’s scientist revealed that they have completed a groundbreaking scientific development determining a set of antibodies that neutralize the novel corona virus.
The president to the state of Israel: “The process is complex and long but your breakthrough is an important scientific millstone toward victory”. ​
 

 

Worldwide breakthrough: A specific monoclonal antibody that is able to effectively neutralize COVID19 was isolated

​IIBR, using its Biology division's well-established platform for antibody engineering, have managed to isolate monoclonal antibody against the virus, from blood samples that were obtain from severe COVID19 patients. It was also demonstrated that this antibody was able to effectively neutralize the virus. Parallel efforts are being made worldwide. Some have managed to isolate antibodies that neutralize other closely related viruses and even anti-SARS-CoV-2 monoclonal antibodies, but IIBR is the first to demonstrate that the antibody that was isolated from COVID19 patient can indeed neutralize this pathogen. IIBR will continue to characterize this antibody and others and a biological manufacture would be sought to mass produce it for clinical use.​​

 

 

The Israel Institute for biological research take on the corona virus's ability to survive on surfaces in low-temperature conditions

​IIBR researchers found that in heat conditions, characterized by the Israeli summer, the virus can survive on the surfaces for several hours compared to a few days at lower temperatures. In their opinion, there is no need for extensive disinfecting of the public spaces towards returning to the work routine 

 

 

Newsroom

Scientific Publications

​IIBR's latest Scientific Publications in the fields of biology, chemistry and the environmental sciences​.

read moreaboutScientific Publications

News

​Read about IIBR in the press.





read moreaboutNews